Public-Private Partnerships

Federal Republic of Germany

In 2010 the Federal Republic of Germany became the official host of the GISAID Initiative through a cooperation agreement with GISAID.

Germany's Federal Ministry of Food and Agriculture (BMEL) oversees through its Federal Office for Agriculture and Food (BLE) the technical hosting arrangements of the GISAID EpiFlu™ database, and through its Friedrich-Loeffler-Institute (FLI) Germany’s Federal Research Institute for Animal Health (a FAO and OIE Collaborating Center) the quality of data in EpiFlu™

United States of America

The United States Department of Health and Human Services, through its Centers for Disease Control and Prevention (CDC) is the first government to support the creation of the GISAID Initiative, by providing since 2007 technical guidance, public funding as well as substantial in-kind contributions for the design and development of the EpiFlu™ database applications and their functionalities.

Singapore

Singapore, through its Agency for Science, Technology and Research (A*STAR) and its Bioinformatics Institute, entered in 2014 into a 5-year cooperation agreement with GISAID on the integration and advancement of the FluSurver tool in the GISAID EpiFlu™ database, to facilitate interpretation of adaptive changes and molecular evolution of influenza viruses, and enhance surveillance.

Sanofi Pasteur’s Foundation for Influenza Epidemiology

The Foundation’s Global Influenza Hospital-based Surveillance Network (GIHSN) was established to increase epidemiological evidence on the burden of severe influenza. In partnership with this initiative, GISAID will help promote the sharing and integration of clinical, epidemiological and virological data to better understand the impact of severe influenza and the benefit of vaccination.

Seqirus

Seqirus, a leading innovator in influenza vaccine technologies and pandemic response solutions, is a contributor to the GISAID public-private partnership, making it the first of its kind from the influenza industry. Seqirus’ commitment will bolster GISAID efforts to advance bioinformatics and the interpretation of influenza data.